Abstract
Insights into the Management of Adverse Events in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Experience from the Phase 3 HELIOS Study of Ibrutinib Combined with Bendamustine/Rituximab
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have